.
Copenhagen, Denmark – Dec. 10, 2025 – CathVision, a medical‑technology firm focused on high‑fidelity cardiac electrophysiology (EP) recording and intelligent analytics, announced two strategic developments: the appointment of Eric Thepaut as independent Chairman of the Board and the commercial launch of ECGenius® System version 3.5.
Eric Thepaut joins CathVision after retiring as President, EMEA, from Boston Scientific (NYSE: BSX). Over a 25‑year career he has overseen multiple cross‑border acquisitions, steered the rollout of the company’s first pulse‑field ablation (PFA) device, and built global commercial operations in more than 30 markets. His expertise in finance, organizational scaling and product commercialization is expected to accelerate CathVision’s entry into the United States and European EP markets.
“CathVision is delivering a new generation of EP recording technology that can significantly improve arrhythmia diagnosis and treatment,” said Eric Thepaut, independent Chairman of the Board. “With ECGenius and the Cardialytics™ suite cleared by the FDA in 2023 and CE‑marked in 2025, the company is positioned for rapid commercial growth.”
The company’s flagship ECGenius® System combines high‑signal‑quality electro‑cardiography with AI‑driven analytics to provide clinicians with clearer, more consistent data during ablation procedures. The newly released version 3.5 introduces several hardware and software upgrades designed to streamline workflow, enhance interoperability, and reduce artefacts that can compromise signal integrity.
- Interface flexibility – users can reorder pages, rename catheters, visualize polarity and adjust analog‑output gain.
- IT integration – studies can be archived in DICOM format and patient information can be auto‑populated from hospital worklists.
- Hardware refinement – updated circuitry reduces post‑pacing artefacts, improving signal fidelity.
- 12‑lead ECG capture – direct logging to the event record accelerates documentation and reduces manual entry.
“These enhancements are a direct response to feedback from physicians and clinical engineers,” said Mads Emil Matthiesen, Chief Technology Officer at CathVision. “Version 3.5 not only strengthens the platform but also paves the way for next‑generation clinical modules, including advanced PFA analytics.”
Market and strategic implications
The global electrophysiology market is projected to exceed $10 billion by 2028, driven by rising prevalence of atrial fibrillation, growing adoption of minimally invasive ablation techniques, and expanding reimbursement frameworks in the U.S. and Europe. CathVision’s focus on high‑resolution signal acquisition and AI‑based interpretation addresses two persistent challenges: variability in signal quality across catheter systems and the time‑consuming nature of post‑procedure analysis.
By integrating DICOM archiving and hospital work‑list connectivity, ECGenius 3.5 aligns with the broader trend of digital health interoperability, enabling hospitals to incorporate EP data into existing imaging and electronic health record (EHR) ecosystems. This capability not only reduces administrative overhead but also creates a data lake for future machine‑learning models, potentially augmenting predictive analytics for arrhythmia recurrence.
The appointment of Eric Thepaut brings a seasoned executive with a proven track record of launching innovative cardiovascular devices in regulated markets. His experience navigating the FDA’s 510(k) and PMA pathways, as well as the European CE‑mark process, is expected to accelerate CathVision’s go‑to‑market strategy. Early pilots of the PFAnalyzer module—designed to quantify lesion formation during PFA—have demonstrated a 15 % reduction in procedure time and a measurable improvement in acute success rates, offering a compelling value proposition for high‑volume EP centers.
Financial analysts note that CathVision’s recent capital raise of $75 million positions the company to scale manufacturing, expand its salesforce, and invest in next‑generation software upgrades. Assuming a conservative capture of 2 % of the U.S. EP market (approximately 1,200 labs) and a comparable share in Europe, projected revenues could reach $120 million within three years, representing a multi‑digit EBITDA margin once economies of scale are realized.
About CathVision
CathVision develops advanced electrophysiology recording hardware and AI‑enabled software aimed at improving the diagnosis and treatment of cardiac arrhythmias. By delivering high‑fidelity signals and actionable analytics, the company seeks to give physicians greater clarity, consistency, and confidence during ablation procedures.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/14318.html
